Last --
Change Today 0.00 / 0.00%
Volume 0.0
4563 On Other Exchanges
Symbol
Exchange
4563 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

anges mg inc (4563) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, is engaged in the research and development, and practical application of genetic medicines. The company is primarily developing Hepatocy growth factor (HGF) genetic medicine, which improves blood circulation by regenerating blood vessels. Its products pipeline includes Collategene for the treatment of peripheral arterial diseases, ischemic heart diseases, Parkinson’s disease, and lymphedema; NFkB decoy oligonucleotide for the treatment of atopic dermatitis and disc degeneration; NFkB decoy oligonucleotide coated PTA balloon catheter for the prevention of vascular restenosis; and CUREPEPTIN functional peptides for the treatment of wounds. The company also provides Naglazyme for the treatment of mucopolysaccharidosis; and CIN therapeutic vaccine for cervical cancer. It has strategic alliances with Daiichi Sankyo Company, Limited for the development of HGF genetic medicine in the fields of peripheral arterial disease and Ischemic heart disease; with Vical, Inc. for the development of Allovectin; and with BioLeaders Corporation for the development of therapeutic vaccine for cervical intraepithelial neoplasia. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc (4563) Key Developments

AnGes MG, Inc. Reports Consolidated and Non- Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2015

AnGes MG, Inc. reported consolidated and non- consolidated earnings results for the year ended December 31, 2014. For the period, the company reported net sales of JPY 909 million against JPY 491 million a year ago. Operating loss was JPY 2,273 million against JPY 1,363 million a year ago. Ordinary loss was JPY 2,395 million against JPY 1,383 million a year ago. Net loss was JPY 2,369 million against JPY 1,409 million a year ago. Net loss per share was JPY 62.12 against JPY 46.91 a year ago. Negative return on equity was JPY 43.1 against JPY 56.9 a year ago. Net assets per share was JPY 142.41 against JPY 107.86 a year ago. Cash flows used in operating activities was JPY 2,703 million against JPY 1,456 million a year ago. For the period, the company reported non- consolidated net sales of JPY 909 million against JPY 491 million a year ago. Operating loss was JPY 2,295 million against JPY 1,415 million a year ago. Ordinary loss was JPY 2,421 million against JPY 1,436 million a year ago. Net loss was JPY 2,386 million against JPY 1,468 million a year ago. Net loss per share was JPY 62.58 against JPY 8.86 a year ago. For the year ending December 31, 2015, the company consolidated expects net sales of JPY 450 million, operating loss of JPY 5,800 million, ordinary loss of JPY 5,800 million and net income JPY 5,800 million or JPY 108.32 per share.

AnGes MG, Inc. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2014

AnGes MG, Inc. revised consolidated earnings guidance for the year ended December 31, 2014. For the year, the company expects net sales between JPY 900 million operating income between JPY 2,400 million, ordinary income between JPY 2,400 million, net income between JPY 2,400 million and net income per share between JPY 62.93 million against previously forecast net sales between JPY 750 million to JPY 850 million operating income between JPY 2,600 million to JPY 2,400 million, ordinary income between JPY 2,600 million to JPY 2,400 million, net income between JPY 2,600 million to JPY 2,400 million and net income per share between JPY 68.17 to JPY 62.93 million.

AnGes MG, Inc., 2014 Earnings Call, Feb 14, 2015

AnGes MG, Inc., 2014 Earnings Call, Feb 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4563:JP ¥304.00 JPY -2.00

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies
 

Industry Analysis

4563

Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGES MG INC, please visit www.anges-mg.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.